(R)-2-(4'-(4-(((1-(2-chlorophenyl)ethoxy)carbonyl)aMino)-3-Methylisoxazol-5-yl)-[1,1'-biphenyl]-4-yl)acetic acid
(R)-2-(4'-(4-(((1-(2-chlorophenyl)ethoxy)carbonyl)aMino)-3-Methylisoxazol-5-yl)-[1,1'-biphenyl]-4-yl)acetic acid Basic information
- Product Name:
- (R)-2-(4'-(4-(((1-(2-chlorophenyl)ethoxy)carbonyl)aMino)-3-Methylisoxazol-5-yl)-[1,1'-biphenyl]-4-yl)acetic acid
- Synonyms:
-
- [1,1'-BIPHENYL]-4-ACETIC ACID, 4'-[4-[[[(1R)-1-(2-CHLOROPHENYL)ETHOXY]CARBONYL]AMINO]-3-METHYL-5-ISOXAZOLYL]-
- {4'-[4-({[(1R)-1-(2-Chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]-4-biphenylyl}acetic acid
- AM 966; AM-966
- CS-2784
- (R)-2-(4'-(4-(((1-(2-chlorophenyl)ethoxy)carbonyl)aMino)-3-Methylisoxazol-5-yl)-[1,1'-biphenyl]-4-yl)acetic acid
- AM 966
- 4'-[4-[[[(1R)-1-(2-Chlorophenyl)ethoxy]carbonyl]amino]-3-methyl-5-isoxazolyl]-[1,1'-biphenyl]-4-acetic acid
- AM966,Lysophospholipid Receptor,inhibit,Inhibitor,AM-966,AM 966,LPL Receptor
- CAS:
- 1228690-19-4
- MF:
- C27H23ClN2O5
- MW:
- 490.93
- Mol File:
- 1228690-19-4.mol
(R)-2-(4'-(4-(((1-(2-chlorophenyl)ethoxy)carbonyl)aMino)-3-Methylisoxazol-5-yl)-[1,1'-biphenyl]-4-yl)acetic acid Chemical Properties
- Boiling point:
- 659.4±55.0 °C(Predicted)
- Density
- 1.330±0.06 g/cm3 (20 ºC 760 Torr)
- storage temp.
- Store at -20°C
- solubility
- ≥24.55 mg/mL in DMSO; insoluble in H2O; ≥2.24 mg/mL in EtOH with gentle warming and ultrasonic
- form
- solid
- pka
- 4.21±0.10(Predicted)
- color
- White to off-white
(R)-2-(4'-(4-(((1-(2-chlorophenyl)ethoxy)carbonyl)aMino)-3-Methylisoxazol-5-yl)-[1,1'-biphenyl]-4-yl)acetic acid Usage And Synthesis
Uses
AM966 is a high affinity, selective, oral LPA1-antagonist, inhibits LPA-stimulated intracellular calcium release (IC50=17 nM).
Biological Activity
am966 is a selective, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (lpa1) with ic50 values of 17 and 19 nm for human or mouse lpa1, respectively [1]. relative to lpa2, 3, 4, 5 receptors, am966 shows 10-fold and 100-fold more selective in mouse and human cell lines for lpa1, respectively [1].
in vitro
am966 shows to inhibit lpa-induced chemotaxis in imr-90 human lung fibroblasts, a2058 human melanoma cells and cho cells expressing lpa1 receptors [1].
in vivo
am966 has been demonstrated to reduce total balf cells, ldh activity, balf collagen and total tgfβ concentrations in bleomycin-induced mice. moreover, am966 has been reported to block lung fibrosis, reduce lung inflammation and maintain body weight in mice induced by bleomycin [1].
target
LPA1 receptor
References
[1] swaney js1, chapman c, correa ld, stebbins kj, bundey ra, prodanovich pc, fagan p, baccei cs, santini am, hutchinson jh, seiders tj,parr ta, prasit p, evans jf, lorrain ds. a novel, orally active lpa(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. br j pharmacol. 2010 aug;160(7):1699-713.
(R)-2-(4'-(4-(((1-(2-chlorophenyl)ethoxy)carbonyl)aMino)-3-Methylisoxazol-5-yl)-[1,1'-biphenyl]-4-yl)acetic acidSupplier
- Tel
- sales@boylechem.com
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Tel
- +86 21 61551611
- Tel
- 021-58950125
- info@chemexpress.com
- Tel
- 400-6206333 13167063860
- anhua.mao@aladdin-e.com